1995
- Technology & Health: Chance of HIV-Tainted Blood Slipping Through Tests Is Believed to Be Lower
- The Wall Street Journal - December 28 1995
- Jerry E. Bishop, Staff Reporter of The Wall Street Journal
- The chances of a unit of HIV-contaminated blood slipping into the nation s blood supplies are fewer than one in a half million, federal and American Red Cross researchers estimated. The probability of AIDS being transmitted by blood transfusions is dropping so low that public health officials may have to consider wheth
- Agouron's AIDS Drug Races Against Time and Titans: Trials Must Start Quickly, Before Competition Grows and Patient Pool Shrinks
- The Wall Street Journal - December 20, 1995
- Rhonda L. Rundle, Staff Reporter of The Wall Street Journal
- SAN DIEGO -- Agouron Pharmaceuticals Inc. is in an unusual race to get its new AIDS drug through human trials. If it doesn t do so before rival drugs flood the market, it will be more difficult to test Agouron s compound on untreated patients, making it harder to prove any competitive advantages. In the dash to com
- Politics & Policy: Insurance Industry's Lobbying and Donations Pay Off Handsomely in Balanced-Budget Bill
- The Wall Street Journal - December 18, 1995
- Christina Duff, Staff Reporter of The Wall Street Journal
- WASHINGTON -- Trying to find the perfect Christmas gift for that hard-to-buy-for insurance agent in the family? Too late, Congress beat you to it. The balanced-budget and tax-cut bill passed last month provides the insurance industry with some gems: tax incentives for consumers to buy private long-term care, for instan
- Technology & Health: First of New Class Of AIDS Drugs Gets FDA Approval
- The Wall Street Journal - December 8, 1995
- Laurie McGinley, Staff Reporter of The Wall Street Journal
- WASHINGTON -- The first of a promising new class of AIDS drugs got Food and Drug Administration approval, but the high price has angered some in the AIDS community. Saquinavir, manufactured by the Hoffmann La-Roche Inc. unit of Roche Holding Ltd., the Swiss pharmaceutical company, is the first so-called protease inhibi
- Technology & Health: Abbott Drug Shows Promise In AIDS Studies
- The Wall Street Journal - December 7, 1995
- Thomas M. Burton, Staff Reporter of The Wall Street Journal
- CHICAGO -- Abbott Laboratories experimental AIDS drug ritonavir was found to be potent in increasing patients immune cells and in reducing levels of the virus in their blood, two newly published studies reported. Ritonavir , one of a promising new class of antiviral compounds known as
- Technology & Health: Proteins Identified That May Slow Progress of AIDS
- The Wall Street Journal - December 7, 1995
- Robert Langreth, Staff Reporter of The Wall Street Journal
- Ending a decade-long search, researchers identified a new family of proteins that may slow the progression of AIDS in people who have been infected with the virus for years but haven t gotten sick. In the test tube, these proteins, which are produced by human immune cells, prevent the AIDS virus -- or HIV -- from repro
- November FDA Drug Approvals: Glaxo's AIDS Drug Tops List
- The Wall Street Journal - December 6, 1995
- With an estimated one million Americans currently infected with the AIDS virus, Glaxo Wellcome s [GLX-NYSE-$27 3/4] new HIV treatment Epivir is especially noteworthy. While far from a cure, it is the first AIDS therapy to be approved by the FDA for first line use in nearly ten years.
- Technology & Health: An FDA Panel Urges Approval of AIDS Drug
- The Wall Street Journal - November 8, 1995
- Laurie McGinley and Anita Womack, Staff Reporters of The Wall Street Journal
- SILVER SPRING, Md. -- In a major step to expand the arsenal of drugs to fight AIDS, a Food and Drug Administration advisory committee urged quick FDA approval of the first of a new class of promising AIDS drugs -- Invirase , made by Hoffmann-LaRoche Inc. Invirase, also known by the generic name saquinavir, is part
- The Deadly Politics of AIDS
- Wall Street Journal - October 25, 1995
- Helen Mathews Smith
- Even though it was clear by the early 1980s that gay bathhouses were a deadly breeding ground for AIDS, Mervyn Silverman, director of the San Francisco Department of Public Health, took three years to decide whether to regulate or close down the bathhouses. In an interview with Frances FitzGerald for her book Cities on
This information is designed to support, not replace, the relationship that exists between you and your doctor.
©1980, 1995. AEGiS.